A Basel-based therapeutics company developing and licensing peptide-based nanoparticle platforms for delivery of nucleic acids to extrahepatic tissues
A Basel-based therapeutics company developing and licensing peptide-based nanoparticle platforms for delivery of nucleic acids to extrahepatic tissues. Its xPhore platform supports siRNA, antisense oligonucleotide, mRNA, circular RNA, and DNA delivery. The company also has preclinical siRNA programs targeting KRAS-driven cancer and rheumatoid arthritis, and markets Bentrio nasal spray.